BIOCON (BIOCON) News
Follow BIOCON (BIOCON) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 19 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Biocon Settles Roche's US Patent Lawsuit Over Proposed Breast-Cancer Biosimilar
Biocon said it settled Genentech's US lawsuit over its proposed biosimilar of the breast-cancer drug Perjeta.
EQUITY | Oct 14, 2026, 06:56 PM UTC
M
Biocon Reaches Global Patent Settlement With Genentech for Pebrilzo
Biocon said it entered a global settlement and license agreement with Genentech for Pebrilzo, its biosimilar to Perjeta. The agreement resolves pending disputes between the companies.
EQUITY | Oct 14, 2026, 10:00 AM UTC
M
Biocon Enters Global Settlement and License Agreement With Genentech for Pebrilzo
EQUITY | Oct 14, 2026, 03:27 AM UTC
M
India Approves Rs 1,600 Crore for 41 Pharma and MedTech Projects
Under the first call of the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), India has approved financial assistance of approximately Rs 1,600 crore for 41 projects. These approved projects are expec
REGULATION | Sep 30, 2026, 04:27 PM UTC
L
True North picks up $50-60 mn stake in IPO-bound InMobi
Mumbai, Sept. 25 -- True North has picked up a stake in initial public offering (IPO)-bound InMobi in a largely secondary transaction, three people familiar with the matter said. The investment is the first technology se
EQUITY | Sep 25, 2026, 02:23 PM UTC
L
Biocon Malaysia gets UK MHRA approval for new drug product fill-finish unit for insulins
Biocon Ltd on Friday said it has received approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for its new drug product fill-finish unit for Semglee (insulin glargine) at its insulin manufact
NEWS | Sep 25, 2026, 10:17 AM UTC
L
Biocon Malaysia arm gets UK regulator approval for Semglee fill finish unit
Biocon Ltd. on Friday, September 25, said its Malaysia arm received approval from the UK drug regulator for its new drug product fill finish unit for Semglee (insulin glargine) at its insulin manufacturing facility in Ma
REGULATION | Sep 25, 2026, 04:48 AM UTC
M
Biocon wins EMA CHMP positive opinion for Pertuzumab biosimilar Pebrilzo
EMA’s CHMP issued a positive opinion recommending EU marketing authorization for Biocon’s Pertuzumab biosimilar Pebrilzo for HER2-positive breast cancer; final European Commission decision is pending.
REGULATION | Sep 22, 2026, 11:58 AM UTC
M
Biocon’s pertuzumab biosimilar gets positive EMA CHMP opinion recommendation
Biocon Biologics says EMA CHMP issued a positive opinion recommending approval for its pertuzumab biosimilar under a tailored clinical approach.
REGULATION | Sep 22, 2026, 11:57 AM UTC
L
Bengaluru CEO fixes broken footpath for Rs.2,700 after lack of action from BBMP; sparks debate on 'DIY governance'
New Delhi, Sept. 15 -- A Bengaluru entrepreneur decided to adopt 'founder mode' for his neighbourhood pavement after years of formal complaints, emails, and automated grievance tickets failed to move the civic authoritie
NEWS | Sep 15, 2026, 11:37 AM UTC
L
True North affiliate sells Rs 638 crore Biocon shares in block deals
Activ Pine LLP, a True North affiliate, offloaded more than Rs 638 crore of Biocon shares via open-market transactions on September 9. After the block deals, Biocon shares ended at Rs 395.
EQUITY | Sep 09, 2026, 04:11 PM UTC
L
Activ Pine LLP sells 16.6 million Biocon shares via block deals
Activ Pine LLP sold 16.6 million shares of Biocon via block deals, according to BSE data referenced by the feed.
EQUITY | Sep 09, 2026, 02:30 PM UTC
L
Biocon shares rise after BSE block deal of 1.65 crore shares
Biocon Ltd. rose after a BSE block deal in the pre-open window. 1.65 crore shares (1% equity) changed hands at ₹385 per share for a ₹630 crore deal value on Wednesday, September 9.
EQUITY | Sep 09, 2026, 03:57 AM UTC
M
Active Pine likely to sell up to 1.66 crore Biocon shares in block
Active Pine LLP is likely to sell up to 1.66 crore Biocon Ltd shares (about 1% equity) via a block deal. The offer size is pegged at ₹638.4 crore, with a floor price of ₹385 per share.
EQUITY | Sep 08, 2026, 01:47 PM UTC
L
Biocon expects double-digit biosimilars growth; targets mid-20% margins
Biocon told CNBC-TV18 it expects double-digit revenue growth in its biosimilars business to continue. The company targets margins in the mid-20% range and expects improvement further.
EARNINGS | Sep 08, 2026, 10:36 AM UTC
M
Biocon shares rise after securing 10-year Pertuzumab supply contract in Brazil
Biocon Ltd. shares gained after the company secured a 10-year supply contract for Pertuzumab in Brazil. It signed a partnership agreement with Bahiafarma and Bionovis for the breast cancer treatment drug.
EQUITY | Sep 08, 2026, 04:26 AM UTC
L
Biocon secures 10-year pertuzumab supply contract in Brazil
Biocon Limited secured a 10-year supply contract for pertuzumab in Brazil, per TradingView News.
EQUITY | Sep 08, 2026, 03:03 AM UTC
L
Avendus Capital MD sees Indian IPOs topping $20 billion this year
India’s equity capital markets may see a little over $20 billion in IPO issuance by year-end, driven by strong primary IPOs, secondary trading and a busy near-term pipeline, Avendus Capital’s MD said.
EQUITY | Sep 03, 2026, 03:33 AM UTC
M
India Centre plans biologics vs synthetics distinction in drug rules
India’s Centre plans changes to the Drugs Rules, 1945 to require pharmaceutical companies to clearly distinguish biologics from synthetic drugs when seeking licences and on packaging, per two government officials.
EQUITY | Sep 02, 2026, 04:08 AM UTC